Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00646880 | A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring | PHASE3 | COMPLETED | 41 | — | — | Mar 1, 2003 | Aug 1, 2003 | Mar 31, 2008 | 1 | South Korea |
| Arm | Type | Description |
|---|---|---|
| Propiverine/tolterodine group | ACTIVE_COMPARATOR | - |
| Tolerodine/propiverine group | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| propiverine | DRUG | Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week. |
| tolterodine PR | DRUG | Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week. |
Inclusion Criteria: * Symptoms of urinary urgency * Symptoms of urinary frequency (greater than or equal to 8 micturitions per 24 hours) as verified on the patient's micturition chart * Symptoms of overactive bladder for greater than or equal to 6 months Exclusion Criteria: * Stress incontinence ...